Krystal Biotech, Inc. (KRYS) Stock Overview
Explore Krystal Biotech, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Krystal Biotech, Inc. (KRYS)
Key Financials
Key Financials
Market Cap
9.2B
P/E Ratio
40.22
EPS (TTM)
$7.48
ROE
0.19%
KRYS Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Krystal Biotech, Inc. (KRYS) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 58.62, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $233.83.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 40.22 and a market capitalization of 9.2B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.